Spectrum Pharmaceuticals Inc
F:NTR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Spectrum Pharmaceuticals Inc
F:NTR
|
US |
|
Akasol AG
XETRA:ASL
|
DE |
|
ADD Industry Zhejiang Co Ltd
SSE:603089
|
CN |
|
Sunyard Technology Co Ltd
SSE:600571
|
CN |
|
W
|
Webull Corp
NASDAQ:BULL
|
US |
|
T
|
Taicera Enterprise Co
VN:TCR
|
VN |
|
Zhong Yang Technology Co Ltd
TWSE:6668
|
TW |
|
BEST Inc
NYSE:BEST
|
CN |
|
M
|
Miahona Holding SCJSC
SAU:2084
|
SA |
|
V
|
Village Farms International Inc
NASDAQ:VFF
|
CA |
|
Danske Andelskassers Bank A/S
CSE:DAB
|
DK |
|
H
|
Hengbo Holdings Co Ltd
SZSE:301225
|
CN |
|
R
|
Rayhoo Motor Dies Co Ltd
SZSE:002997
|
CN |
|
C
|
CHCX Resources Inc
OTC:CHCX
|
US |
Spectrum Pharmaceuticals Inc
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of late-stage clinical and commercial products. The company is headquartered in Henderson, Nevada and currently employs 163 full-time employees. The firm's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of late-stage clinical and commercial products. The company is headquartered in Henderson, Nevada and currently employs 163 full-time employees. The firm's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
